Pharmaceutical Industry
Filter News
Found 52,883 articles
-
AbbVie’s $10.1 billion ImmunoGen buy and Altimmune’s Phase II win demonstrate that the antibody-drug conjugate market is red hot in cancer and GLP-1 drugs for weight loss are an absolute craze.
-
While Pfizer’s oral GLP-1 candidate met its primary endpoint in a Phase IIb obesity trial, twice-daily dosing of danuglipron resulted in high rates of adverse events including nausea, vomiting and diarrhea.
-
Citing slow enrollment and low clinical rates, the late-stage “evidence trials” are being discontinued. AstraZeneca said there are no safety concerns and no impact on Lokelma’s current approved indication.
-
CEO Emma Walmsley projects that the British biopharma’s Arexvy sales will exceed £1 billion in its first year on the market, leaving Pfizer’s Abrysvo respiratory syncytial virus vaccine far behind in the race.
-
The company is hoping the topline results for Veozah, which won FDA approval in May, will support health technology assessments for reimbursement negotiations in Europe.
-
The company’s investigational c-Met protein directed antibody-drug conjugate showed a “compelling” overall response rate in patients with previously treated non-small cell lung cancer.
-
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
12/1/2023
HUTCHMED Limited highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology Asia Congress, taking place on December 1-3, 2023 in Singapore, and the ESMO Immuno-Oncology Congress, taking place on December 6-8, 2023 in Geneva, Switzerland.
-
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
12/1/2023
Innovent Biologics, Inc. announces the publication of updated clinical data of IBI351 monotherapy in non-small cell lung cancer and colorectal cancer at the European Society for Medical Oncology Asia Congress 2023, held during December 1-3 in Singapore.
-
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
12/1/2023
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc") announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.
-
Opthea to Present at the FLORetina 2023 Congress
12/1/2023
Opthea Limited announced an oral presentation featuring sozinibercept which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
-
GC Biopharma establishes mRNA production facility in Hwasun, Korea
12/1/2023
GC Biopharma, a South Korean biopharmaceutical company, announced on November 30th that it has completed the construction mRNA production facility in its own vaccine production plant in Hwasun, Jeollanam-do, Korea, and will soon start the operation.
-
Calliditas announces additions to the management team - December 01, 2023
12/1/2023
Calliditas Therapeutics AB announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.
-
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
12/1/2023
Ono Pharmaceutical Co., Ltd. announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P., which was established as a corporate venture capital fund in CA, USA in May 2020.
-
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
12/1/2023
Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.
-
Facing the loss of Humira revenues from biosimilar competition, AbbVie is looking to grow its pipeline by acquiring ImmunoGen and its antibody-drug conjugate Elahere, which was granted FDA accelerated approval last year.
-
The two companies have settled all pending U.S. patent litigation, clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of Stelara.
-
Despite a recent Phase II miss, Xenon Pharmaceuticals is forging ahead with its candidate for major depressive disorder, offering 8.4 million common shares for sale.
-
Opinion: How to Vet Your Next Company
11/30/2023
Consider each company using three different criteria: its match with the candidate’s “why,” its financial health and its employee reviews. -
The troubled Indian pharma company received its second FDA warning letter in months, which this time cited quality control and data integrity lapses at its manufacturing facility in Gujarat, India.
-
Engineers help their employers remain efficient, GMP-compliant and up-to-date on the latest technologies and industry trends.